Q: How can a company best navigate the complexities of all the tactical options—strategic partnering, collaborations, licensing,
another financing round and M&A?
A: Clearly understanding the financial risks and benefits of all options is the first step. However, other factors must be
considered—how much control is the company willing to cede? What decision-making responsibilities are most important to the
company and the long-term success of the drug or technology? What areas of expertise does the company have and where is it
Today's deal-making environment offers many options for life sciences companies. Companies need to fully understand the options—and
the risks and rewards—related to strategic alliances and M&A so they can make the best decisions to preserve long-term enterprise
value and also to enhance the probability of success.
Sergio Garcia is co chair of the life sciences group, and partner, corporate and intellectual property group, at Fenwick & West LLP, San
Francisco, CA, 415.875.2366, email@example.com